282 related articles for article (PubMed ID: 14586644)
21. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model.
Kisker O; Becker CM; Prox D; Fannon M; D'Amato R; Flynn E; Fogler WE; Sim BK; Allred EN; Pirie-Shepherd SR; Folkman J
Cancer Res; 2001 Oct; 61(20):7669-74. PubMed ID: 11606410
[TBL] [Abstract][Full Text] [Related]
22. Endostatin inhibits the tumorigenesis of hemangioendothelioma via downregulation of CXCL1.
Guo L; Song N; He T; Qi F; Zheng S; Xu XG; Fu Y; Chen HD; Luo Y
Mol Carcinog; 2015 Nov; 54(11):1340-53. PubMed ID: 25175281
[TBL] [Abstract][Full Text] [Related]
23. Assessment of antiangiogenic effect using 99mTc-EC-endostatin.
Yang DJ; Kim KD; Schechter NR; Yu DF; Wu P; Azhdarinia A; Roach JS; Kalimi SK; Ozaki K; Fogler WE; Bryant JL; Herbst R; Abbruzzes J; Kim EE; Podoloff DA
Cancer Biother Radiopharm; 2002 Apr; 17(2):233-45. PubMed ID: 12030117
[TBL] [Abstract][Full Text] [Related]
24. Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice.
Jia YH; Dong XS; Wang XS
World J Gastroenterol; 2004 Nov; 10(22):3361-4. PubMed ID: 15484319
[TBL] [Abstract][Full Text] [Related]
25. Thalidomide and angiostatin inhibit tumor growth in a murine xenograft model of human cervical cancer.
Downs LS; Rogers LM; Yokoyama Y; Ramakrishnan S
Gynecol Oncol; 2005 Aug; 98(2):203-10. PubMed ID: 15975645
[TBL] [Abstract][Full Text] [Related]
26. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
Thomas JP; Arzoomanian RZ; Alberti D; Marnocha R; Lee F; Friedl A; Tutsch K; Dresen A; Geiger P; Pluda J; Fogler W; Schiller JH; Wilding G
J Clin Oncol; 2003 Jan; 21(2):223-31. PubMed ID: 12525513
[TBL] [Abstract][Full Text] [Related]
27. E-selectin is required for the antiangiogenic activity of endostatin.
Yu Y; Moulton KS; Khan MK; Vineberg S; Boye E; Davis VM; O'Donnell PE; Bischoff J; Milstone DS
Proc Natl Acad Sci U S A; 2004 May; 101(21):8005-10. PubMed ID: 15148373
[TBL] [Abstract][Full Text] [Related]
28. A reinforced random walk model of tumour angiogenesis and anti-angiogenic strategies.
Plank MJ; Sleeman BD
Math Med Biol; 2003 Jun; 20(2):135-81. PubMed ID: 14636027
[TBL] [Abstract][Full Text] [Related]
29. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
Sasaki T; Larsson H; Kreuger J; Salmivirta M; Claesson-Welsh L; Lindahl U; Hohenester E; Timpl R
EMBO J; 1999 Nov; 18(22):6240-8. PubMed ID: 10562536
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of vascular endothelial growth factor and integrinbeta3 by endostatin in a mouse model of retinal neovascularization.
Zhang M; Yang Y; Yan M; Zhang J
Exp Eye Res; 2006 Jan; 82(1):74-80. PubMed ID: 16198337
[TBL] [Abstract][Full Text] [Related]
31. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
32. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
[TBL] [Abstract][Full Text] [Related]
33. Numerical simulation of the inhibitory effect of angiostatin on metastatic tumor angiogenesis and microenvironment.
Zhao G; Yan W; Chen E; Yu X; Cai W
Bull Math Biol; 2013 Feb; 75(2):274-87. PubMed ID: 23292363
[TBL] [Abstract][Full Text] [Related]
34. Tat PTD-endostatin: A novel anti-angiogenesis protein with ocular barrier permeability via eye-drops.
Zhang X; Li Y; Cheng Y; Tan H; Li Z; Qu Y; Mu G; Wang F
Biochim Biophys Acta; 2015 Jun; 1850(6):1140-9. PubMed ID: 25662072
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status.
Anakha J; Dobariya P; Sharma SS; Pande AH
Med Oncol; 2023 Dec; 41(1):24. PubMed ID: 38123873
[TBL] [Abstract][Full Text] [Related]
36. Effect of human recombinant Endostatin protein on human angiogenesis.
Jung SP; Siegrist B; Hornick CA; Wang YZ; Wade MR; Anthony CT; Woltering EA
Angiogenesis; 2002; 5(1-2):111-8. PubMed ID: 12549868
[TBL] [Abstract][Full Text] [Related]
37. Endostatin induces proliferation of oral carcinoma cells but its effect on invasion is modified by the tumor microenvironment.
Alahuhta I; Aikio M; Väyrynen O; Nurmenniemi S; Suojanen J; Teppo S; Pihlajaniemi T; Heljasvaara R; Salo T; Nyberg P
Exp Cell Res; 2015 Aug; 336(1):130-40. PubMed ID: 26112215
[TBL] [Abstract][Full Text] [Related]
38. [Tumor angiogenesis inhibitors: media and scientific aspects].
Raymond E
Presse Med; 1998 Jul 4-11; 27(24):1221-4. PubMed ID: 9767782
[TBL] [Abstract][Full Text] [Related]
39. Combined Anti-PLGF and Anti-Endostatin Treatments Inhibit Ocular Hemangiomas.
Jiang H; Wu X; Wang H; Huang C; Zhang L
Cell Physiol Biochem; 2015; 36(3):930-6. PubMed ID: 26088746
[TBL] [Abstract][Full Text] [Related]
40. Functionalized nanospheres loaded with anti-angiogenic drugs: cellular uptake and angiosuppressive efficacy.
Hammady T; Rabanel JM; Dhanikula RS; Leclair G; Hildgen P
Eur J Pharm Biopharm; 2009 Jun; 72(2):418-27. PubMed ID: 19462478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
